Generation Bio Co. (GBIO) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.53 per share a year ago. These figures ...

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.26 on $83.94 million in revenues for ...

The commercial-stage biotechnology company posted revenue of $73.7 million for the quarter, missing the consensus estimate of $77. ... For the full year 2024, Iovance reported total product ...

The company forecasted revenue in the range of $165 million to $175 million, whereas the consensus estimate was $186.9 ... development earlier in the year. On January 13, Illumina Inc (NASDAQ ...

Read Full Bio Editor in Chief ... When you fill out your annual federal income tax return, you can either take the standard deduction or itemize deductions to reduce your taxable income.

Operating income decreased by 11.4% to €2.6 million from € ... no obligation to update or revise the information contained in this press release. Estimated Full-Year 2024 Consolidated Financial ...

Toronto, Ontario--(Newsfile Corp. - March 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company”), a clinical stage pharmaceutical company dedicated to the ...

For the quarter, the company's total revenue amounted to $667.5 million, experiencing a decline of 2% year over year. Next, we'll explore the breakdown of BIO's international revenue to understand ...